Pneumoconiosis future or investigational therapies

Jump to navigation Jump to search

Pneumoconiosis Microchapters


Patient Information


Historical Perspective




Differentiating Pneumoconiosis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumoconiosis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Pneumoconiosis future or investigational therapies

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumoconiosis future or investigational therapies

CDC on Pneumoconiosis future or investigational therapies

Pneumoconiosis future or investigational therapies in the news

Blogs on Pneumoconiosis future or investigational therapies

Directions to Hospitals Treating Pneumoconiosis

Risk calculators and risk factors for Pneumoconiosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD


Future therapies for pneumoconiosis are being considered.

Future or Investigational Therapies

Future therapies are being experimented on including inhibiting cytokines and the use of antioxidants. Investigational therapy also includes administration of bone marrow-derived mononuclear cells. [1] [2] [3] In the case of berylliosis, the use of 5-aminosalicylic acid (ASA) is being considered as it improved the beryllium lymphocyte proliferation test (BeLPT) test by 20% after use for six weeks. [4] The use of tetrandrine, which is found in Chinese medical "han fang ji" has been experimented on and not proven effective. [5]


  1. Rimal B, Greenberg AK, Rom WN (2005). "Basic pathogenetic mechanisms in silicosis: current understanding". Curr Opin Pulm Med. 11 (2): 169–73. doi:10.1097/01.mcp.0000152998.11335.24. PMID 15699791.
  2. Maron-Gutierrez T, Castiglione RC, Xisto DG, Oliveira MG, Cruz FF, Peçanha R; et al. (2011). "Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis". Eur Respir J. 37 (5): 1217–25. doi:10.1183/09031936.00205009. PMID 20693250.
  3. Cavalli G, Fallanca F, Dinarello CA, Dagna L (2015). "Treating pulmonary silicosis by blocking interleukin 1". Am J Respir Crit Care Med. 191 (5): 596–8. doi:10.1164/rccm.201412-2150LE. PMID 25723826.
  4. Day BJ, Huang J, Barkes BQ, Gillespie M, Li L, Maier LA (2018). "5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects". Lung. 196 (1): 103–114. doi:10.1007/s00408-017-0062-x. PMID 29080069.
  5. Li QL (1981). "[The therapeutic effect of tetrandrine on silicosis (author's transl)]". Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi. 4 (6): 321–3. PMID 7344866.

Template:WH Template:WS